Antiviral activity in vitro of two preparations of the herbal medicinal product Sinupret registered against viruses causing respiratory infections

• Published in: Phytomedicine (Stuttgart) Vol. 19; no. 1; pp. 1 - 7
• Main Authors: Glatthaar-Saalmueller, B, Rauchhaus, U, Rode, S, Haunschild, J, Saalmueller, A
• Format: Journal Article
• Language: English
• Published: 15.12.2011
• Subjects: Adenovirus; Coxsackievirus; Human rhinovirus; Primula; Respiratory syncytial virus; Verbena
• ISSN: 0944-7113
• DOI: 10.1016/j.phymed.2011.10.010

Sinupret registered , a herbal medicinal product made from Gentian root, Primula flower, Elder flower, Sorrel herb, and Verbena herb is frequently used in the treatment of acute and chronic rhinosinusitis and respiratory viral infections such as common cold. To date little is known about its potential antiviral activity. Therefore experiments have been performed to measure the antiviral activity of Sinupret registered oral drops (hereinafter referred to as "oral drops") and Sinupret registered dry extract (hereinafter referred to as "dry extract"), in vitro against a broad panel of both enveloped and non-enveloped human pathogenic RNA and DNA viruses known to cause infections of the upper respiratory tract: influenza A, Chile 1/83 (H1N1) virus (FluA), Porcine Influenza A/California/07/2009 (H1N1) virus (pFluA), parainfluenza type 3 virus (Para 3), respiratory syncytial virus, strain Long (RSV), human rhinovirus B subtype 14 (HRV 14), coxsackievirus subtype A9 (CA9), and adenovirus C subtype 5 (Adeno 5). Concentration-dependent antiviral activity (EC sub(50) between 13.8 and 124.8 mu g/ml) of Sinupret registered was observed against RNA as well as DNA viruses independent of a viral envelope. Remarkable antiviral activity was shown against Adeno 5, HRV 14 and RSV in which dry extract was significantly superior to oral drops. This could be ascertained with different assays as plaque-reduction assays in plaque forming units (PFU), the analyses of a cytopathogenic effect (CPE) and with enzyme immunoassays (ELISA) to determine the amount of newly synthesised virus. Our results demonstrate that Sinupret registered shows a broad spectrum of antiviral activity in vitro against viruses commonly known to cause respiratory infections.